Understanding the risks of thrombosis in CALR-mutated MPN patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the expression levels of TLR 2 and TLR 4 on mononuclear cells in patients with CALR mutation-positive myeloproliferative neoplasms (MPN) and compare these levels to those in patients with JAK2 V617F mutations and healthy controls. Participants will provide blood samples during standard care blood draws, and their demographic and clinical data will be collected. The study seeks to uncover the underlying reasons for the increased risk of thrombosis in patients with JAK2 mutations compared to those with CALR mutations. It will initially be conducted at a single center, the Wake Forest Baptist Comprehensive Cancer Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Written (or electronic) informed consent and HIPAA authorization for release of personal health information by participant or his/her legally authorized representative (LAR).
* Age ≥ 18 years at the time of enrollment
* Diagnosis of myeloproliferative neoplasm (MPN) according to 2022 World Health Organization classification of MDS/MPNs
* CALR-positive genetic mutation

Exclusion Criteria:

\- Diagnosis of MPN with JAK2 V617F mutation

Where it's running

• Atrium Health Levine Cancer
  Charlotte, North Carolina, United States Recruiting
• Wake Forest Baptist Comprehensive Cancer Center
  Winston-Salem, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Aleksander Chojecki, MD — Atrium Health Levine Cancer
• Study coordinator: Courtney Schepel
• Email: Courtney.Schepel@atriumhealth.org
• Phone: (980) 292-0817

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Caris Chromoseq data collection for AML, MDS, and MPN

  This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.

  Recruiting Caris Science, Inc. · Phoenix, Arizona · NCT07680868

• Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms

  This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.

  Recruiting University Hospital, Bordeaux · Angers and 14 other locations · NCT07119970

• CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant

  This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.

  Recruiting at 3 sites Phase 1 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07020533

• Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant

  This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT06815003

• Study of characteristics and complications in young patients with myeloproliferative neoplasia

  This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.

  Recruiting University Hospital, Brest · Brest · NCT06715267

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.